Zeeshan Javed1,2, Maria Papageorgiou1,3, Harshal Deshmukh1, Alan S Rigby4, Unaiza Qamar5, Jehangir Abbas2, Amer Y Khan6, Eric S Kilpatrick7, Stephen L Atkin8, Thozhukat Sathyapalan1. 1. Department of Academic Diabetes, Endocrinology and Metabolism, Hull York Medical School, University of Hull, Hull, UK. 2. Department of Endocrinology and Diabetes, Pakistan Kidney & Liver Institute and Research Centre, Lahore, Pakistan. 3. Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology, and Immunology, Medical University of Vienna, Vienna, Austria. 4. Hull York Medical School, University of Hull, Hull, UK. 5. Department of Pathology, Pakistan Kidney & Liver Institute and Research Centre, Lahore, Pakistan. 6. Department of Medicine, Pakistan Kidney & Liver Institute and Research Centre, Lahore, Pakistan. 7. Department of Pathology, Sidra Medical and Research Center, Doha, Qatar. 8. Weill Cornell Medical College Qatar, Doha, Qatar.
Abstract
BACKGROUND:Empagliflozin is a sodium-glucose-cotransporter-2 inhibitor that improves cardiovascular risk and promotes weight loss in patients with type-2 diabetes. Polycystic ovary syndrome (PCOS) is associated with obesity and increased cardiovascular risk; therefore, empagliflozin may be of benefit for these women. The aim of this study was to compare the effects of empagliflozin vs metformin on anthropometric and body composition, hormonal and metabolic parameters in women with PCOS. MATERIALS AND METHODS: A randomized open-label study was conducted in women with PCOS who were randomized to either empagliflozin 25 mg (n = 19) or metformin 1500 mg (n = 20) daily for 12 weeks. The main outcomes assessed were changes in anthropometric and body composition, hormonal and metabolic parameters. RESULTS: Univariate analysis showed significant differences in weight (empagliflozin: -1.4 ± 3.2% vs metformin: 1.2 ± 2.3%; P = 0.006), body mass index (empagliflozin: -1.4 ± 3.2% vs metformin: 1.1 ± 2.2%; P = 0.006), waist circumference (empagliflozin: -1.6 ± 2.8% vs metformin: 0.2 ± 2.1%; P = 0.029) and hip circumference (empagliflozin: -2.0 ± 3.0% vs metformin: 1.1 ± 1.9%; P = 0.001), basal metabolic rate (empagliflozin: -1.8 ± 2.9% vs metformin: 0.1 ± 1.9%, P = 0.024) and fat mass (empagliflozin: -0.7 ± 4.9% vs metformin, 3.2 ± 5.0%; P = 0.023) between the empagliflozin and the metformin groups. These differences were confirmed in linear regression analysis after adjustment for relevant covariates. There were no significant changes in hormonal or metabolic parameters between both groups. CONCLUSION: There was a significant improvement in anthropometric parameters and body composition, in overweight and obese women with PCOS after 12 weeks of treatment with empagliflozin compared to metformin, although no changes were seen in hormonal or metabolic parameters.
RCT Entities:
BACKGROUND:Empagliflozin is a sodium-glucose-cotransporter-2 inhibitor that improves cardiovascular risk and promotes weight loss in patients with type-2 diabetes. Polycystic ovary syndrome (PCOS) is associated with obesity and increased cardiovascular risk; therefore, empagliflozin may be of benefit for these women. The aim of this study was to compare the effects of empagliflozin vs metformin on anthropometric and body composition, hormonal and metabolic parameters in women with PCOS. MATERIALS AND METHODS: A randomized open-label study was conducted in women with PCOS who were randomized to either empagliflozin 25 mg (n = 19) or metformin 1500 mg (n = 20) daily for 12 weeks. The main outcomes assessed were changes in anthropometric and body composition, hormonal and metabolic parameters. RESULTS: Univariate analysis showed significant differences in weight (empagliflozin: -1.4 ± 3.2% vs metformin: 1.2 ± 2.3%; P = 0.006), body mass index (empagliflozin: -1.4 ± 3.2% vs metformin: 1.1 ± 2.2%; P = 0.006), waist circumference (empagliflozin: -1.6 ± 2.8% vs metformin: 0.2 ± 2.1%; P = 0.029) and hip circumference (empagliflozin: -2.0 ± 3.0% vs metformin: 1.1 ± 1.9%; P = 0.001), basal metabolic rate (empagliflozin: -1.8 ± 2.9% vs metformin: 0.1 ± 1.9%, P = 0.024) and fat mass (empagliflozin: -0.7 ± 4.9% vs metformin, 3.2 ± 5.0%; P = 0.023) between the empagliflozin and the metformin groups. These differences were confirmed in linear regression analysis after adjustment for relevant covariates. There were no significant changes in hormonal or metabolic parameters between both groups. CONCLUSION: There was a significant improvement in anthropometric parameters and body composition, in overweight and obesewomen with PCOS after 12 weeks of treatment with empagliflozin compared to metformin, although no changes were seen in hormonal or metabolic parameters.
Authors: Zeeshan Javed; Maria Papageorgiou; Leigh A Madden; Alan S Rigby; Eric S Kilpatrick; Stephen L Atkin; Thozhukat Sathyapalan Journal: Endocr Connect Date: 2020-06 Impact factor: 3.335
Authors: Jack Alistair Sargeant; Joseph Henson; James Adam King; Thomas Yates; Kamlesh Khunti; Melanie Jane Davies Journal: Endocrinol Metab (Seoul) Date: 2019-09
Authors: Jacob E Pruett; Edgar D Torres Fernandez; Steven J Everman; Ruth M Vinson; Kacey Davenport; Madelyn K Logan; Stephanie A Ye; Damian G Romero; Licy L Yanes Cardozo Journal: Int J Mol Sci Date: 2021-03-04 Impact factor: 5.923
Authors: Yao Hao Teo; Yao Neng Teo; Nicholas L Syn; Cheryl Shumin Kow; Celine Shuen Yin Yoong; Benjamin Y Q Tan; Tiong-Cheng Yeo; Chi-Hang Lee; Weiqin Lin; Ching-Hui Sia Journal: J Am Heart Assoc Date: 2021-02-24 Impact factor: 5.501